ALB and kidney disorder: The MARLINA-T2DM (efficacy, safety, and modification of albuminuria in type 2 diabetes subjects with renal disease with linagliptin) trial is ongoing, in order to evaluate the albumin-lowering potential of linagliptin in T2DM patients with renal impairment [283].